UNRESECTABLE COLORECTAL CARCINOMA
Clinical trials for UNRESECTABLE COLORECTAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE COLORECTAL CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE COLORECTAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…
Matched conditions: UNRESECTABLE COLORECTAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail shows promise for Tough-to-Treat colorectal cancer
Disease control OngoingThis study tests a combination of three drugs (cetuximab, LY3214996, and abemaciclib) in people with advanced colorectal cancer that has spread and no longer responds to standard therapy. The goal is to see if the combination can shrink tumors and improve survival. About 46 adult…
Matched conditions: UNRESECTABLE COLORECTAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug called M6620 (berzosertib) combined with the chemotherapy irinotecan in people with advanced solid tumors that have spread or can't be removed. The goal is to find the safest dose and see if the combination can slow tumor growth. About 66 p…
Matched conditions: UNRESECTABLE COLORECTAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New immune cell therapy trial for advanced cancers withdrawn before starting
Disease control TerminatedThis early-stage trial aimed to test the safety of a new treatment called STIL101 for people with advanced pancreatic, colorectal, kidney, cervical cancer, or melanoma that has spread or cannot be removed. STIL101 is made from a patient's own immune cells taken from their tumor, …
Matched conditions: UNRESECTABLE COLORECTAL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC